Global Information
회사소개 | 문의 | 비교리스트

세계의 치매 치료제 시장(2020-2026년)

리서치사 Orion Market Research Pvt Ltd
발행일 발행예정 상품 코드 949563
페이지 정보 영문
가격
US $ 3,600 ₩ 4,252,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,670,000 Printable PDF (Enterprise License)


세계의 치매 치료제 시장(2020-2026년)
발행일 : 발행예정 페이지 정보 : 영문

세계 치매 치료제 시장은 예측기간 중 높은 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 치매는 적어도 뇌의 두가지 기능장애를 일으킵니다. 치매의 가장 일반적인 뇌기능 장애에는 판단력 상실과 기억력 상실이 있습니다. 시장 성장을 촉진하는 주요인에는 치매, 알츠하이머병, 파킨슨병 등에 걸리기 쉬운 고령자 인구가 전세계적으로 증가하고 있는 것이 포함됩니다.

세계 치매 치료제 시장 조사에서는 시장에서 활동하는 다양한 기업을 다루었습니다. 세계 치매 치료제 시장에서 활동하고 있는 주요 기업으로는 Boehringer Ingelheim GmbH, Teva Pharmaceuticals Industries Ltd., Merck&Co. Inc., Pfizer Inc., GlaxoSmithKline Plc, Aurobindo Pharma Ltd., Biogen Inc.등이 있습니다.

세계의 치매 치료제(Dementia Drugs) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 유형별·지역별 시장 규모 추이와 예측, 주요 기업 개요, 시장 기회 등의 정보를 전해드립니다.

목차

제1장 보고서 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트 인사이트와 현재 시장 동향
  • 규칙과 규제

제3장 경쟁 구도

  • 주요 전략 분석
  • 주요 기업 분석
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceuticals Industries Ltd.
    • Merck&Co. Inc.
    • Pfizer Inc.
    • GlaxoSmithKline Plc

제4장 시장 영향요인

  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회

제5장 시장 세분화

  • 치매 유형별
    • 루이소체 치매
    • 파킨슨병 치매
    • 알츠하이머병 치매
    • 기타
  • 약제 유형별
    • 콜린에스테라제 차단제
    • MAO 저해제
    • 글루타민산 저해제
    • 기타

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제7장 기업 개요

  • Abbvie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Apotex Corp.
  • Aurobindo Pharma Ltd.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Impax Laboratories, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vertical Pharmaceuticals, LLC
  • Zydus Pharmaceuticals, Inc.
LSH

LIST OF TABLES

  • 1. GLOBAL DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2019-2026 ($ MILLION)
  • 2. GLOBAL LEWY BODY DEMENTIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL PARKINSON'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ALZHEIMER'S DISEASEMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL OTHERS DEMENTIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUGS, 2019-2026 ($ MILLION)
  • 7. GLOBALCHOLINESTERASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL MAO INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL GLUTAMATE INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL OTHER DRUGSMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUGS, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2019-2026 ($ MILLION)
  • 15. EUROPEAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. EUROPEAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUGS, 2019-2026 ($ MILLION)
  • 17. EUROPEAN DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUGS, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DRUGS, 2019-2026 ($ MILLION)
  • 22. REST OF THE WORLD DEMENTIA DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE OF DEMENTIA, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL DEMENTIA DRUGS MARKET SHARE BY TYPE OF DEMENTIA, 2019 VS 2026 (%)
  • 2. GLOBAL DEMENTIADRUGS MARKET SHARE BY TYPE OF DRUGS, 2019 VS 2026 (%)
  • 3. GLOBAL DEMENTIADRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD DEMENTIADRUGS MARKET SIZE, 2019-2026 ($ MILLION)

Global Dementia Drugs Market Size, Share & Trends Analysis Report By Type of Dementia (Lewy Body Dementia, Parkinson's Disease, Alzheimer's Disease, and Others), By Type of Drug (Cholinesterase Inhibitors, MAO Inhibitors, Glutamate Inhibitors, and Others), and Forecast 2020-2026

The global dementia drugsmarket is anticipated to grow at a significant CAGR during the forecast period. Dementia is a group of condition that results in impairment of the brain's at least two functions. The most common impaired brain functions in dementia include loss of judgment as well as memory. The major factor contributing to the growth of the market includesthe increasing geriatric population across the globe as they are more prone to dementia and its related conditions such as Alzheimer's and Parkinson's.

The global dementia drugs market is segmented on the basis of the type of dementia and type of drugs. Based on the type of dementia, the market is sub-segmented into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease dementia, and others such as vascular dementia. Alzheimer's disease segment is expected to exhibit a lucrative growth during the forecast period. Further based on the type of drugs, the market is sub-segmented into cholinesterase inhibitors, MAO inhibitors, Glutamate inhibitors, and others.

The global dementia drugs market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World.North America is expected to hold a significant share in the market during the forecast period. The growth in the region is due to the well-developed healthcare sector engaged in providing its elderly population with better healthcare facilities for the conditions such as Parkinson's disease and Alzheimer disease.Asia-Pacific is estimated to exhibit a significant growth rate in the global cluster headache market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Moreover, the study of the global dementia drugs market report covers the analysis of various players operating in the market. Some of thekey players operating inthe global dementia drugsmarket includeBoehringer Ingelheim GmbH, Teva Pharmaceuticals Industries Ltd.,Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline Plc, Aurobindo Pharma Ltd., Biogen Inc., and others.

Research Methodology

The market study of the global dementia drugsmarket is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for the pharmaceutical industry, drug manufacturers, hospitals& clinics,government organizations, regulatory bodies, and other market participantsfor overall market analysis and competitive analysis.The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. GlobalDementiaDrugsMarket Research and Analysis by Type of Dementia

2. Global Dementia Drugs Market Research and Analysis by Type of Drug

The Report Covers:

  • Comprehensive research methodology of the global dementia drugsmarket.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global dementia drugsmarket.
  • Insights about market determinants which are stimulating the global dementia drugsmarket.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Key Strategy Analysis
  • 3.2. Key Company Analysis
    • 3.2.1. Boehringer Ingelheim GmbH
      • 3.2.1.1. Overview
      • 3.2.1.2. Financial Analysis
      • 3.2.1.3. SWOT Analysis
      • 3.2.1.4. Recent Developments
    • 3.2.2. Teva Pharmaceuticals Industries Ltd.
      • 3.2.2.1. Overview
      • 3.2.2.2. Financial Analysis
      • 3.2.2.3. SWOT Analysis
      • 3.2.2.4. Recent Developments
    • 3.2.3. Merck & Co. Inc.
      • 3.2.3.1. Overview
      • 3.2.3.2. Financial Analysis
      • 3.2.3.3. SWOT Analysis
      • 3.2.3.4. Recent Developments
    • 3.2.4. Pfizer Inc.
      • 3.2.4.1. Overview
      • 3.2.4.2. Financial Analysis
      • 3.2.4.3. SWOT Analysis
      • 3.2.4.4. Recent Developments
    • 3.2.5. GlaxoSmithKline Plc
      • 3.2.5.1. Overview
      • 3.2.5.2. Financial Analysis
      • 3.2.5.3. SWOT Analysis
      • 3.2.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Dementia Drugs Market by Type of Dementia
    • 5.1.1. Lewy Body Dementia
    • 5.1.2. Parkinson's Disease Dementia
    • 5.1.3. Alzheimer's Disease Dementia
    • 5.1.4. Others
  • 5.2. Global DementiaDrugsMarket by Type of Drugs
    • 5.2.1. Cholinesterase Inhibitors
    • 5.2.2. MAO Inhibitors
    • 5.2.3. GlutamateInhibitors
    • 5.2.4. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbvie Inc.
  • 7.2. ACADIA Pharmaceuticals Inc.
  • 7.3. Apotex Corp.
  • 7.4. Aurobindo Pharma Ltd.
  • 7.5. Biogen Inc.
  • 7.6. Boehringer Ingelheim GmbH
  • 7.7. Eisai Co., Ltd.
  • 7.8. Eli Lilly and Co.
  • 7.9. GlaxoSmithKline Plc
  • 7.10. Impax Laboratories, Inc.
  • 7.11. Johnson & Johnson Services, Inc.
  • 7.12. Merck & Co. Inc.
  • 7.13. Mylan NV
  • 7.14. Novartis International AG
  • 7.15. Pfizer Inc.
  • 7.16. Teva Pharmaceutical Industries Ltd.
  • 7.17. Vertical Pharmaceuticals, LLC
  • 7.18. Zydus Pharmaceuticals, Inc.
Back to Top
전화 문의
F A Q